At PeptidePeak, our main goal is to equip researchers, clinicians, and lab professionals with high-purity, research-grade peptides for advanced laboratory studies. Our catalog features a broad selection of compounds used for research regarding aging biology, cellular signaling, and endocrine regulation.
CJC-1295 is a growth hormone-releasing peptide that’s commonly used in biometrical research. CJC-1295, which is a synthetic peptide, works as an analogue of growth hormone-releasing hormone (GHRH). It’s widely known for its unique pharmacokinetic profile, which is primarily enabled by bioconjugation using drug affinity complex (DAC) technology.
Here, we’ll gather the most recent and important information regarding CJC-1295 injection, including study results on metabolic stability, molecular architecture, and clinical applications, as well as its potential in human studies. By the end, you’ll understand the specifics of CJC-1295 and why it, along with other peptides, raises such interest among researchers.
WORTH KNOWING: CJC-1295 and Ipamorelin are available for research purposes only and should be purchased from reputable sources. It requires a prescription from a licensed physician for safe acquisition. PeptidePeak is an example of a trustworthy supplier with top-notch peptides available for research.
CJC-1295 is a synthetic peptide analog of the GH-releasing hormone receptor protein created from 30 amino acids. In some sense, the compound is a tetrasubstituted derivative of the native GHRH(1-29) sequence, strategically engineered to enhance its pharmacokinetic properties and resistance to enzymatic degradation. Most of the data we have come from rodent models and large animal models, though clinical pharmacokinetic studies in humans are quite promising as well. Below, we examine its molecular profile and biological activity.
CJC-1295 contains a modified version of the first 29 amino acids in the chain of GHRH to improve its stability. A Drug Affinity Complex (DAC) in the composition allows it to bind to serum albumin to guarantee a longer half-life. This modification demands fewer injections while still maintaining satisfactory GH and IGF-1 levels. Thus, the peptide is available in two forms: a long-lasting GRF analog (with DAC) and a standard form (without DAC). Key molecular characteristics include:
Comparative Pharmacokinetic Profile: CJC-1295 with DAC vs. without DAC
| Parameter | CJC-1295 with DAC | CJC-1295 without DAC (Mod GRF 1-29) |
|---|---|---|
| Estimated half-life | 5.8–8.1 days | ~30 minutes |
| Albumin binding | Yes (covalent, via DAC) | No |
| GH elevation duration (single dose) | 6+ days | 1–3 hours |
| IGF-1 elevation duration (single dose) | 9–11 days | Hours |
| Mean GH increase | 2- to 10-fold above baseline | Transient pulse only |
| Mean IGF-1 increase | 1.5- to 3-fold above baseline | Modest, short-lived |
| Dosing frequency | Weekly or biweekly | Multiple times daily |
Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. Yet, it does so much more behind the scenes. The injection has demonstrated beneficial effects on insulin-like growth factor, fat metabolism, recovery, and sleep. Even though biochemical characteristics of CJC-1295 describe it as a synthetic GHRH analog, it cannot be a replacement for the growth hormone itself; the solution’s primary task is to stimulate the pituitary gland harmoniously to make its natural pulses more frequent, thus increasing the natural level of GH in the organism.
Regarding the mechanism of action of CJC-1295, it activates the GHRH receptor, leading to increased intracellular cAMP levels and subsequent activation of protein kinases that promote growth hormone synthesis. It is a common practice to use it with another peptide, Ipamorelin, which activates the ghrelin receptor, mobilizes intracellular calcium, and activates protein kinase C, leading to immediate growth hormone secretion.
The duo enhances the beneficial effects of the injection: while CJC-1295 primarily increases the amplitude of growth hormone pulses, Ipamorelin modulates their frequency. Together, they act synergistically on the growth hormone axis. Ionescu and Frohman (2006) confirmed that CJC-1295 increases trough and mean GH secretion and IGF-1 production while preserving natural GH pulsatility — notably, basal GH levels rose 7.5-fold and overall mean GH levels increased by 46%.
This finding is particularly significant as it demonstrates that CJC-1295 augments GH output without disrupting the body’s normal pulsatile secretion pattern. Regarding Ipamorelin specifically, Raun et al. (1998) described ipamorelin as a pentapeptide displaying high GH releasing potency in vitro and in vivo, and — crucially — found it did not elevate ACTH or cortisol plasma levels even at doses more than 200-fold above the GH ED50, distinguishing it from other secretagogues such as GHRP-6 and GHRP-2.
Mechanistic Comparison: CJC-1295 vs. Ipamorelin
| Feature | CJC-1295 | Ipamorelin |
|---|---|---|
| Receptor target | GHRH receptor (GHRHR) | Ghrelin receptor (GHSR-1a) |
| Intracellular signaling | ↑ cAMP → Protein Kinase A activation | ↑ intracellular Ca²⁺ → Protein Kinase C activation |
| Primary GH effect | Increases amplitude of GH pulses | Modulates frequency of GH pulses |
| Effect on ACTH/cortisol | No significant elevation | No significant elevation (selective) |
| Half-life | 5.8–8.1 days (with DAC) | ~2 hours |
| Combined effect | Synergistic stimulation of the GH/IGF-1 axis |
Some users may experience fatigue or lethargy as a side effect of CJC-1295 and Ipamorelin; headache and injection site reactions are possible as well, which is why it’s highly recommended to only use this injection under the observance of a qualified medical professional. Some researchers claim that chronic use of CJC-1295 may lead to increased insulin resistance or decreased insulin sensitivity.
CJC-1295 combined with Ipamorelin has been studied in multiple fields, far beyond the androgen receptor. Below, we’ll examine the research application of the two peptides in more detail.
Unlike direct growth hormone injections used for GH synthesis, CJC-1295’s main advantage is its ability to stimulate endogenous pulsatile GH secretion, which mimics physiological conditions more closely. That characteristic is particularly beneficial for studies in research models that examine the significance of pulsatile vs. continuous GH exposure on gene expression patterns, metabolic outcomes, and downstream signaling. The research is mainly concentrated on comparative studies of GH replacement opportunities, GH receptor regulation and desensitization, as well as tissue-specific responses to GH responses of various natures. In a pair of randomized, placebo-controlled, double-blind trials in healthy subjects aged 21–61, Teichman et al. (2006) demonstrated that a single subcutaneous injection of CJC-1295 produced dose-dependent GH increases lasting 6 or more days, while IGF-1 remained elevated for 9–11 days. After repeated dosing, mean IGF-1 levels stayed above baseline for up to 28 days, and no serious adverse reactions were reported.
Key Clinical Findings from the Teichman et al. (2006) Study
| Outcome Measure | Result |
|---|---|
| GH increase (single dose) | 2- to 10-fold above baseline for ≥6 days |
| IGF-1 increase (single dose) | 1.5- to 3-fold above baseline for 9–11 days |
| IGF-1 elevation after multiple doses | Above baseline for up to 28 days |
| Estimated CJC-1295 half-life | 5.8–8.1 days |
| Best-tolerated dose range | 30–60 µg/kg (subcutaneous) |
| Serious adverse reactions | None reported |
The connection between GH/IGF-1 and the aging process is a hot topic for discussion among researchers. The studies mainly examine the changes the body undergoes with age, including sarcopenia (age-related muscle loss) and increased adiposity. Experimental models in animal studies demonstrated that CJC-1295 treatment can partially reverse age-related reduction in lean mass and bone density; however, further extensive investigation is required to apply these results to human studies. In a proteomic study by Sackmann-Sala et al., sera from 11 healthy young adult men were analyzed before and one week after CJC-1295 injection using two-dimensional gel electrophoresis.
The research identified significant changes in serum protein profiles – including decreases in an apolipoprotein A1 isoform and a transthyretin isoform, as well as increases in several protein spots – suggesting these may serve as novel biomarkers of GH and/or IGF-1 action.
Considering GH and IGF-1 naturally play a significant role in the tissue repair process, no wonder CJC-1295 has found its place in studies that investigate its beneficial effect on wound healing, bone fracture repair, and muscle injury recovery, as well as lean mass and subcutaneous fat mass. In animal studies, CJC-1295 shows promising results in stimulating collagen production, thereby accelerating wound closure and improving tissue remodelling.
In addition, CJC-1295-treated animals showed better callus formation and faster attainment of mechanical strength than controls. Even though its clinical application requires further investigation, these findings still demonstrate its great potential for recovery from orthopedic injuries.
GH and IGF-1 are known for their anabolic effects, leading to increased interest from researchers in studies that cover the fields of muscle hypertrophy, strength development, and athletic performance. During preclinical studies, animals treated with CJC-1295 that participated in resistance exercise training demonstrated apparent increase in lean body mass accretion, in addition to increased muscle fiber cross-sectional zone and contractile protein synthesis.
However, we must emphasize that CJC-1295 is prohibited in competitive athletics by the World Anti-Doping Agency (WADA) for performance-enhancing purposes. The research in this area is limited by controlled laboratory studies that examine the physiological mechanisms GH/IGF-1 have on muscle tissue, with no approval for non-therapeutic use. However, it demonstrates great potential in neuromolecular medicine.
Summary of CJC-1295 Research Areas and Evidence Status
| Research Area | Primary Model | Key Outcome Observed | Evidence Stage |
|---|---|---|---|
| GH deficiency / replacement | Human (RCT) | Sustained GH and IGF-1 elevation; preserved pulsatility | Phase I/II human trials |
| Aging / sarcopenia | Animal models | Partial reversal of lean mass and bone density loss | Preclinical; human data limited |
| Tissue repair / wound healing | Animal models | Enhanced collagen synthesis, improved callus formation | Preclinical |
| Body composition | Animal models | Increased lean body mass, muscle fiber hypertrophy | Preclinical; WADA-prohibited in sport |
| Sleep architecture | Human / Animal | Potential enhancement of slow-wave sleep and GH release | Preliminary / observational |
Previous studies suggested that CJC-1295 may potentially improve sleep architecture by perfecting slow-wave (deep) sleep phases during which natural growth hormone release peaks typically happen. In addition to subjective sleep quality measures, there’s also a potential recovery processes enhancement, which is associated with GH release during the deep sleep phase. These findings are quite significant for aging research, as well as for recovery optimization studies in rehabilitation and athletic fields.
No. CJC-1295 is not FDA-approved for human medical use. Its long-term effects on humans are not yet well studied; therefore, it’s impossible to guarantee a safe experience for patients. However, in some cases, this product is used under a therapist’s observation, and even though this method is not fully safe, it’s the only acceptable form of using CJC-1295 for humans.
CJC-1295 is often sought for increases in lean muscle mass, fat loss, improved deep sleep, and anti-aging benefits. Its results are promising for athletes and individuals with growth hormone deficiency; therefore, researchers have invested substantial effort in human studies of CJC-1295 to develop the safest possible formulation, and the work still continues.
No. CJC-1295 is not classified as a dietary supplement and is not approved for therapeutic use. Even though the data on aging research and metabolism studies are quite promising, its therapeutic usage is not supported by regulatory agencies and should be considered experimental.
Not really. CJC-1259 is typically administered to signal the pituitary gland to produce more GH in steady pulses to increase growth hormone levels, but it doesn’t replace the GH itself. When combined with Ipamorelin (peptide also known as a selective growth hormone secretagogue), CJC-1259 delivers the best results: while Ipamorelin improves pulsatile secretion of GH, CJC-1259 provides a more prolonged stimulation, which closely mimics the body’s natural pattern of hormone release.
No. HGH is a synthetic growth hormone that is delivered through an injection. CJC-1295 is a peptide that guarantees a continuous stimulation of the pituitary gland for a natural GH release in the body.
It’s impossible to provide an exact number, as the product’s cost varies with purity, supplier, and quantity. Research-grade CJC-1259 typically ranges from several hundred dollars, based on the quality standard and synthesis methods.
Yes, always. Under current peptide regulations, licensed professionals and research institutions must provide valid credentials or institutional documentation to purchase CJC-1295 for research purposes.
Lyophilized (powder) vials with CJC-1295 must be stored in a freezer at -20 °C or below for long-term storage; it may also be kept in the refrigerator (2-8 °C) for several months. Once reconstituted with bacteriostatic water, the peptide should be refrigerated (2-8 °C) and used within a few weeks.
CJC-1295 with DAC contains a Drug Affinity Complex that enables it to bind albumin, thereby extending its half-life to 6-8 days. The variation without DAC (Mod GRF 1-29) has a half-life of around 30 minutes, thus a more frequent administration is required. Another difference is that the DAC version provides a stable GH increase, while the non-DAC option creates more acute GH pulses.
You must be logged in to post a review.
There are no reviews yet.